MAY 13, 2020 5:48 PM PDT

Approved Treatment for RET-mutant Cancers

WRITTEN BY: Nouran Amin

A drug was recently approved for treating three types of RET-mutant cancers: 1) non-small cell lung cancer (NSCLC) 2) advanced or metastatic RET-mutant medullary thyroid cancer (MTC) that may require systemic therapy and 3) advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

Learn more:

The FDA-approved drug by Eli Lily and Company is Retevmo™ (selpercatinib, 40 mg & 80 mg capsules) which came after findings of a LIBRETTO-001 clinical trial.

"In the clinical trial, we observed that the majority of metastatic lung cancer patients experienced clinically meaningful responses when treated with selpercatinib, including responses in difficult-to-treat brain metastases," said Alexander Drilon, M.D., acting chief of early drug development at Memorial Sloan Kettering Cancer Center and lead investigator for LIBRETTO-001. "The approval of selpercatinib marks an important milestone in the treatment of NSCLC, making RET-driven cancers now specifically targetable in the same manner as cancers with activating EGFR and ALK alterations, across all lines of therapy. I am pleased that patients with these RET-driven cancers have this newly approved option."

Retevmo is an oral prescriptive medication that works as a selective RET kinase inhibitor and may target both tumor cells and healthy cells.

"RET alterations account for the majority of medullary thyroid cancers and a meaningful percentage of other thyroid cancers. For patients living with these cancers, the approval of selpercatinib means they now have a treatment option that selectively and potently inhibits RET," said Lori J. Wirth, M.D., medical director of head and neck cancers, Massachusetts General Hospital Cancer Center. "Based on the published data for this new medicine, as well as my personal experience treating patients, this may be a good treatment option."

Source: Eli Lilly

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
MAY 04, 2020
Immunology
MAY 04, 2020
GeoVax and Sino Bio Collaborate on COVID-19 Vaccine Work
GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and ...
MAY 12, 2020
Immunology
MAY 12, 2020
Disabling Genes in Immune Cells Prevents Obesity
Obesity is a $1.7 trillion problem in the United States — a value almost 10% of the nation’s gross domestic ...
MAY 06, 2020
Cancer
MAY 06, 2020
Olanzapine useful for cancer patients managing nausea unrelated to chemo
A study published last week in JAMA Oncology reports that a generic drug called Olanzapine could be useful for cancer pa ...
MAY 13, 2020
Drug Discovery & Development
MAY 13, 2020
Drug Targets Off Episodes of Parkinson
A novel drug was approved by the FDA to target the “off” episodes of Parkinson disease. The drug is referred ...
JUN 14, 2020
Cell & Molecular Biology
JUN 14, 2020
A Fungal Compound That Triggers Self-Destruction in Cancer Cells
To describe it in a very basic way, cancer is uncontrolled cell growth. A number of processes regulate various aspects o ...
JUN 12, 2020
Technology
JUN 12, 2020
How A Computer Sea Slug Can Get Addicted To A Drug
Sea slugs have long been used to study brain models especially in research concerned with memory and learning. Now, rese ...
Loading Comments...